[The effect of antiprotein plasma on humoral resistance in children with severe burns]

Klinicheskaia Khirurgiia
|January 1, 1992
PubMed

Insights

In severely burned children, key blood markers like alpha 2-macroglobulin and fibronectin decrease during toxemia. Treatment with donor antiproteic plasma shows positive therapeutic effects for burn-related toxic syndromes.

Area of Science:

  • Biochemistry
  • Pediatric Medicine
  • Trauma Care

Context:

  • Severely burned children often develop toxemia and septic toxemia.
  • The acute phase of these conditions involves significant physiological changes.
  • Monitoring specific blood serum components is crucial for assessing disease severity.

Purpose:

  • To investigate alterations in specific blood serum components during toxemia in severely burned children.
  • To correlate these biochemical changes with the development and progression of toxic syndromes.
  • To evaluate the therapeutic efficacy of donor antiproteic plasma.

Summary:

  • In severely burned children, decreased anti-triptic activity, alpha 2-macroglobulin, fibronectin, and arginase activity were observed during acute toxemia and septic toxemia.
  • Concurrently, there was a significant increase in fibrin-fibrinogen degradation products.
  • These alterations in studied indices are informative regarding the toxic syndrome's dynamics.

Impact:

  • The findings highlight key biomarkers for monitoring toxic syndrome in pediatric burn patients.
  • Understanding these biochemical shifts aids in predicting disease progression.
  • Donor antiproteic plasma demonstrates a beneficial therapeutic effect, suggesting its potential role in managing severe burn complications.

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...